Olaratumab: PDGFR-α inhibition as a novel tool in the treatment of advanced soft tissue sarcomas

Antonio Russo, Giuseppe Badalamenti, Francesco Pantano, Massimo Aglietta, Andrea Napolitano, Mariella Spalato Ceruso, Bruno Vincenzi, Giovanni Grignani, Giuseppe Tonini, Daniele Santini, Daniele Santini

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Advanced soft tissue sarcomas are aggressive cancers with limited therapeutic options. Recently, inhibition of platelet-derived growth factor receptor (PDGFR)-α by the monoclonal antibody olaratumab showed promising clinical activity. If confirmed, this would be one of the first examples of targeted therapy effective in advanced soft tissue sarcomas therapy independently of the histologic subtype. Here, we reviewed the biology of the PDGF/PDGFR axis, particularly focusing on its role in cancer, and then we discussed on the effects of PDGFR-α inhibition in the therapy of advanced soft tissue sarcomas.
Original languageEnglish
Pages (from-to)1-6
Number of pages6
JournalCRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
Volume118
Publication statusPublished - 2017

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology
  • Geriatrics and Gerontology

Cite this

Russo, A., Badalamenti, G., Pantano, F., Aglietta, M., Napolitano, A., Spalato Ceruso, M., Vincenzi, B., Grignani, G., Tonini, G., Santini, D., & Santini, D. (2017). Olaratumab: PDGFR-α inhibition as a novel tool in the treatment of advanced soft tissue sarcomas. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 118, 1-6.